Reimbursement diligence for an additive-manufacturing platform in healthcare.

A publicly traded additive-manufacturing (3D printing) company was evaluating which of its platform's healthcare-adjacent applications warranted commercial investment in the U.S. market. The technology could produce patient-specific devices across several clinical categories — but a capability that can be manufactured is not the same as a product that can be billed, covered, and paid.

The company needed a rigorous, independent view of the U.S. reimbursement landscape across its candidate applications: which use cases had established codes and coverage, which would require years of policy development, and where the revenue math actually worked. Without that view, leadership risked directing capital toward applications that would never reach payment.

Wellguidant Advisors assessed the reimbursement viability of each candidate application as a distinct market entry, structured around the coding-coverage-payment framework.

• Application-by-application coding analysis: Determined for each use case whether billable codes already existed (CPT, HCPCS, or codes for similar devices that could be used), and what the realistic pathway and timeline to new codes would be where they didn't.
• Coverage assessment: Mapped each application against Medicare national and local coverage policy — including device-specific LCDs and the durable medical equipment and prosthetics frameworks where patient-specific devices typically land — distinguishing genuine coverage gaps from gaps that were merely undocumented.
• Payment economics: Benchmarked expected payment rates for comparable devices across care settings, and modeled how site-of-service and payer mix would shape realized revenue for each application.
• Comparative prioritization: Synthesized the findings into a comparative view across applications — reimbursement readiness, time to first revenue, and policy risk — so leadership could rank investment opportunities on reimbursement reality rather than technical enthusiasm.

The company received a decision-ready map of where its platform could generate U.S. healthcare revenue, where it couldn't yet, and why. Leadership could direct commercial investment toward the applications with established or near-term reimbursement pathways while treating the longer-horizon applications as evidence-development bets rather than launch commitments.

For platforms whose technology spans many possible clinical uses, the most expensive mistake is choosing applications on what the technology can do rather than on what payers will pay for. Grounding the portfolio decision in coding, coverage, and payment reality converted an open-ended exploration into a prioritized commercial strategy.